Global Information, Inc.
¤é°ÓÀô²y°T®§¦³­­¤½¥q
ºô¯¸¾ÉÄý
²£·~/¥«³õ¤ÀÃþ
»sÃÄ¥ø·~
¦³¿³½ì°Ñ»P¥þ²y°ê»Ú·|ij(®i¥Ü·|)¶Ü?
Pharmaceutical Companies Market Research

»sÃÄ¥ø·~¥«³õ½Õ¬d³ø§i®Ñ¶°

Global Information, Inc. ´£¨Ñ±z»sÃÄ¥ø·~©Ò¦³¬ÛÃö¥DÃDªº¥«³õ/²£·~±¡³ø¡C

°£¤F»sÃÄ¥ø·~¥~¡AGII ¤]¨ÑÀ³¨ä¥L««ª½¾ã¦X²£·~ªº¥«³õ¬ã¨s¡B²£·~¹w´ú¤Î¥ø·~¤ÀªR¡C§Ú­Ìªº±¡³ø°Ó«~¤À§O¥H½Õ¬d³ø§i®Ñ¡B¸ê®Æ®w¡B·s»D¥Xª©«~¡A¤Î¦~«×¸ê°TªA°Èªº§Î¦¡´£¨Ñ±z³Ì·sªº²£·~¹w´ú¡B­p¹º¡BÁͶաB¥«³õ¦û¦³²v¡B¬ì§Þ¬ãµo¡B¾P°âÃB»P¦æ¾Pµ¦²¤¡A¤ÎÄvª§¤ÀªR¡C¨C¶g5¤Ñ¡A¨C¤Ñ24¤p®É¡A§Ú­Ì¥H¦hºØ»y¨¥ÀH®É¬°±zªA°È¡C½Ð¨ì§Ú­ÌªºÁpµ¸¸ê°Tºô­¶Contact page¤W½T»{­þ¤@­Ó¿ì¤½«Ç¥¿©ó¤W¯Z®É¶¡¡A¨ÃÅwªï»P§Ú­ÌªºªA°È¥NªíÁpµ¸¨Ó¨ó§U±z¥H³Ì§Öªº³t«×§ä¨ì±z»Ý­nªº±¡³ø°Ó«~¡C


Alcon Inc.¡G»sÃÄ¥ø·~²¤¶
Alcon Inc.: PharmaVitae Profile
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111677

»P¯f±w¤ä´©¹ÎÅé¨ó¤O¶i¦æ¥«³õ±Ð¨|
Collaborating with Patient Advocacy Groups to Educate the Marketplace
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111630

ºÞ²z·ÓÅU³¡ªù°w¹ï³B¤èÃľ¯¤§§Q¥Î«P¶i¡]pull-through¡^µ¦²¤
Developing Managed Care Pull-Through Excellence
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111629

¥H¯f±w¬°¤¤¤ß¡G»P¯f±w±µÄ²¡B«Ø¥ßÃö«Y¡B¤ä´©¤§­Ó®×¬ã¨s
Innovations in Patient-Focused Initiatives: Case Studies in Reaching, Engaging and Supporting Patients
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111625

ÂåÀø±Ð¨|­pµe°Ñ¥[ªÌ¶Ò¶°¤§³Ì¨Î®×¨Ò¬ã¨s
Best Practices in Recruitment for Medical Education Programs
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111623

¤W¥««á½Õ¬dÃĪ«¤£¨}¨Æ¥ó¤§³Ì¨Î®×¨Ò¬ã¨s¡G¬ü°ê¥«³õ
Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S. 
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109074

«~µP»P¯f±¡¤§¤º³¡·¾³q³Ì¨Î®×¨Ò¤ÀªR
Best Practices for Internal Communications Regarding Brands & Disease States
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 108548

¨È¬wªºÂåÃĦ@¦P¬ãµo¾÷ºc¡]CRO¡^¡G2010¦~
Contract Research Organizations in Asia 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 108308

©t¨àÃÄ«~ªº¾÷·|¡G´£¤É±q§Q°ò©Ê¾AÀ³¤W³Ì¤j§Q¯qªº¾Ô²¤
Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106674

ÂåÃÄ«~©e¥~¬ãµoªº¥¼¨Óµo®i¡G¶}µo¤WªºªùÂe¥H¤Î¦³®Ä¬¡¥ÎCROªº¥D­n½ÒÃD»Pµ¦²¤
The Future of R&D Outsourcing: Investigating development hurdles, key challenges & strategies to optimize CRO relationships
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106663

·P¬V¯g¥«³õªº¥D­n¥ø·~:¥D­n¨ÑÀ³ªÌ¤Îªñ´X¦~·s¥[¤J¥ø·~ªº·§ªp
Leading Infectious Disease Market Players: Insightful Profiles of Major Suppliers and Recent Market Entrants
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106505

Wyeth¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Wyeth: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106495

Virbac¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Virbac: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106494

¥þ²y«e¤Q¤j°Êª«ÂåÀøÃÄ«~¼t°Ó
Top Ten World's Leading Animal Health Companies
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106493

Schering-Plough¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Schering-Plough: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106492

Pfizer¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Pfizer: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106491

Novartis¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Novartis: Performace, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106490

Merial¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Merial: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106489

Elanco¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Elanco: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106480

Bayer¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Bayer: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106479

Alpharma¡G¥@¬É°Êª«ÂåÃÄ¥«³õªº¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Î¾Ô²¤
Alpharma: Performance, Capabilities, Goals and Strategies in the Worldwide Animal Health Market
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 106478

¦L«×»sÃIJ£·~¥«³õ³ø§i®Ñ
The Pharmaceutical Market: India
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 25611

¨ü°U»s³yÂåÀøÃÄ«~¾÷ºcªº®i±æ¡G¨ì2015¦~¬°¤îªº¥«³õ¹w´ú»P¥D­n°Ê¦V
The Future of Contract Manufacturing - Market Forecasts to 2015 and Key Trends
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 108043

»sÃĤ½¥q®i±æ¡G¡ã2014¦~
Pharmaceutical Company Outlook to 2014
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 107848

¥NÁ©ʯe¯fªvÀøÃĪº¥¼¨Ó:¨ì2015¦~¬°¤îªº¥«³õ¹w´ú¡BÄvª§©Ê¼Ð¬ñºÞ²z¡B²£«~ºÞ¹D¡B¥æ©ö¤ÀªR
The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 106800

¥þ¥@¬É¬Ì­]ªº¥¼¨Ó:¨ì2016¦~¬°¤îªº¥«³õ¹w´ú¡BÀx³Æ¤ÀªR¡BÄvª§©Ê¼Ð¬ñºÞ²z¤ÎºÞ¹D¤ÀªR
The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 106799

¼Ú¬w¦Ê¤j»sÃļt°Ó·§ªp
The Top 100 European Manufacturers Of Finished Pharmaceuticals
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 106282

2009¦~ÂåÃÄ«~·~¬ÉªºM&A°Ê¦V
2009 Pharmaceutical M&A Overview
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 105779

¤j«¬»sÃĤ½¥qªº¤j«¬¦X¨Ö¡G1995¡ã2014¦~
Big Pharma Mega-Mergers 1995-2014
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 105430

¦bÀù¯g»â°ì¥ø·~¥æ©ö¡R¥æ©öºc³y©M»ù­Èµû»ù
Analysis of Oncology Deals: Trends in Deal Structures and Valuations
¥Xª©¤é´Á : 2009/12
°Ó«~½s½X : 104712

¸gÀÙ¤£´º®ð«e¡B¤£´º®ð®É¡B¤£´º®ð«á¤§¤j«¬»sÃĤ½¥q¤§·~ÁZ
Big Pharma Performance Before, During and Beyond the Global Recession
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 105142

¥D­nÃĪ«µ¹ÃÄ¥ø·~ªº¶}µo°Ê¦V
Who's Developing What in Drug Delivery?
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 103589

¨º¦Ì¤ñ¨ÈªºÂåÀø·~¬É·§­n
Overview of the Healthcare Industry in Namibia
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 103197

ÂåÃÄ«~¥Í©R¶g´ÁºÞ²zªº³Ì¾A·í¤Æ¡G¼Ð¥ÜªºÂX¤j©M²V¦X»s«~ªº¹Ø©R©µªø
Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 103178

¨ü°U»s³yÂåÀøÃÄ«~¤§¾÷ºc¡]CMO¡^¥«³õ¤§®i±æ¡G·s¿³¥«³õ¡BÃöÁä¬ãµo¥ø·~¡B¤µ«á¤§°Ê¦V
The Cmo Market Outlook: Emerging markets, key players and future trends
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 103176

ªZ¥ÐÃÄ«~¤u·~¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Takeda: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 42303

½Ã§÷¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Eisai: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 42295

»sÃÄ¥ø·~¤ÀªR³ø§i¡GNovartis
Novartis: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/11
°Ó«~½s½X : 17140

¤¤°êÂåÃÄ«~³sÂê²£·~:2009¦~
China Pharmaceutical Chain Industry Report, 2009
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 108196

ÃÄ«~·~¬Éªº¦X¨Ö»P¨ÖÁÊ
Pharmaceutical Mergers and Acquisitions
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 102381

ÃÄ«~ªº©e°U»s³y¡A¬ã¨s»P¥]¸Ë¡Q2009¦~ª©
Contract Pharmaceutical Manufacturing, Research and Packaging
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 102343

Ävª§¤ÀªR¡G¾®¦å¦]¤l
Competitor Analysis: Coagulation Factors
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 102247

¥þ²y«D±M§QÃÄ«~¥ø·~«ü«n¡]2009¦~¡^
Partnering in the Global Generics Industry 2009: A guide to companies
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 101214

ÃÄ«~²£·~ªººtÁ¿ªÌ­pµe¡GROI´ú¶q¤Î»ù­È¶Ç¹F
Pharmaceutical Speaker Programs - Measuring ROI and Communicating Value
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 101076

ÃÄ«~・¥Íª«¬ì§Þ»â°ìµ¹Ãħ޳N¬ÛÃö¦X§@¦X¬ù°Ê¦V
Drug Delivery Partnering Agreements in Pharma and Biotech
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 101043

²Ä¤@¤T¦@¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Daiichi Sankyo: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 42293

¤¤¥~»sÃÄ¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Chugai: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 42291

«ô¦Õ¡]Bayer¡^¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Bayer: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/10
°Ó«~½s½X : 25000

Wyeth¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Wyeth: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103168

Sanofi-Aventis¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Sanofi-Aventis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103167

Roche¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Roche: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103166

Pfizer¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Pfizer: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103165

Novartis¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Novartis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103164

Merck¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Merck: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103163

Johnson & Johnson¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Johnson & Johnson: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103162

GlaxoSmithKline¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
GlaxoSmithKline: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103161

Bristol-Myers Squibb¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
Bristol-Myers Squibb: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103160

AstraZeneca¡G¥þ²yÂåÃÄ«~¥«³õ¤§¹êÁZ»P¯à¤O¡B¥Ø¼Ð¤Îµ¦²¤
AstraZeneca: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103159

¥D­nÂåÃÄ«~¥ø·~¤§°]°È¤ÀªR
Leading Pharmaceutical Companies Financial Analyses
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 103152

¥­¦æ¥æ©ö¤ÎÃÄ«~³q¸ô°°ÃĪº¼vÅT¡G½ÒÃD¤Î¹ïµ¦¡B°w¹ï¨ÑÀ³Ãì¾ã¦Xªº¬Ýªk
Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, initiatives and insights for supply chain integrity
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 100892

¤£´º®ð¹ïÃÄ«~²£·~M&A³y¦¨ªº¼vÅT
The Recession and its Impact on Pharmaceutical M&A Activity
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 100797

EGF-R«P®ÄÃĤιï§ÜÃÄ¡GÄvª§¤ÀªR
Competitor Analysis: EGF-R Agonists and Antagonists
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 100177

ÂåÃÄ«~·~¬ÉªºM&A°Ê¦V¡G·s¿³°Ê¦V¤Î¥i¹w´ú¤§ºZ¾P«áªº¥Ø¼Ð¹ï¶H
The Evolving Pharma M&A Landscape: Emerging trends and predicted post-blockbuster targets
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 99423

¶EÂ_ÃÄ»â°ìªº¦X§@¦X¬ù
Partnering Agreements in Diagnostics
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 99256

Recordati¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Recordati: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 17860

Solvay »sÃĤ½¥q±¡³ø³ø§i®Ñ
Solvay: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 15838

»sÃÄ¥ø·~¤ÀªR³ø§i¡GBoehringer Ingelheim
Boehringer Ingelheim: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/09
°Ó«~½s½X : 13856

CRO¥«³õªº®i±æ¡G·s¿³¥«³õ¡B¥D­n¥ø·~¡B¤Î±N¨Ó°Ê¦V
The CRO Market Outlook: Emerging markets, leading players and future trends
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 99393

¾®¦å¦]¤l¡]2009¦~¡^¡G¼Ðªº²£«~½u¤ÎÄvª§¼Ð¬ñ¤ÀªR
Coagulation Factors 2009: Target Pipeline and Competitor Benchmark Analysis
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 98543

ÃÄ«~¾P°â¹Î¶¤ªº¦³®Ä©Êµ¦²¤¡GÅU«È¬°¥Dµ¦²¤ªº¾P°â¼Ò¦¡¤Î³Ì·s§Þ³Nµû»ù
Pharmaceutical Sales Force Effectiveness Strategies: Evaluating evolving sales models & advanced technology for a customer centric approach
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 97738

¯«¸g¯e¯f¤§²£«~½u¡Gµ¦²¤©Ê¦^ÅU
The Neurology Pipeline: A Strategic Review
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 97066

Shire¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Shire: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 66458

¨ó©Mµo»Ã¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Kyowa Hakko: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 42296

¼b¥Í¶°¹Î¡G»s»sÃÄ¥ø·~¤ÀªR³ø§i
Johnson & Johnson: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 20875

Sanofi・aventis¡G»sÃÄ¥ø·~¤ÀªR³ø§i
sanofi-aventis: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/08
°Ó«~½s½X : 16660

¥þ²y«e10¤j¥D­n¥Íª«ªU§Þ¥ø·~¡G²£·~・°]°È・SWOT¤ÀªR
Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 101026

¨Ï¥Î¥~³¡¨Ó·½ªº¦­´Á¿é°eºÞ¹D«Øºc¾Ô²¤
Strategies for Building Early-Stage Pipelines Through External Sources
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 97067

±N«eÁ{§É¬ã¨s©e¥~µ¹¤¤°ê¡GÀuÂI¤Î½ÒÃD
Outsourcing Preclinical Studies to China: Benefits and Challenges Overview
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96402

PI3K-AKT-mTOR§í¨î¾¯¥«³õªºÄvª§¤ÀªR
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96355

²Õ´³J¥Õ¥h¤AñQ×Q§í¨î¾¯¥«³õªºÄvª§¤ÀªR
Competitor Analysis: HDAC Inhibitors
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96354

ÃÄ«~²£·~¶±¥ÎªÌ¥«³õªºµ¦²¤¤Î¾Ô³N
Serving the Healthcare Needs of Employers: Employer Market Strategies and Tactics
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96340

¥þ²yÃÄ«~¤Î¥Íª«¬ì§Þ²£·~CEOªº¥þ¤è¦ì¹w´ú
CEO 360 Degree Perspective - Global Pharmaceuticals & Biotechnology Industry
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96216

°ª¦åÀ£ÃÄ¡G·sªº¦h¾¯²V¦XÃÄ¡]FDC¡^µLªk¨î¤î±M§Q¥¢®ÄªºÁͶÕ
Commercial Insight: Antihypertensives - New fixed dose combinations unable to stem the tide of patent expiries
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96201

°®Å~¡G´¼¼z°]²£«P¶i¦¨ªø
Commercial Insight: Psoriasis - Intellectual property drives growth
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 96199

°Ó·~¥æ©ö»P·~¬ÉÆ[¹î:¦ÛÅé§K¬Ì¯f±w»Pµoª¢©Ê¯f±w
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 95542

ÃÄ«~・¥Íª«¬ì§Þ・¶EÂ_²£·~ªº»s³y・¨Ñµ¹¦X¬ù
Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics, 2nd edition
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 95303

´£°ª»sÃÄ¥ø·~¥Í²£®Ä²vªº¾P°â°V½m
Managing Sales Training to Accelerate Speed to Productivity
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 95274

¦³®Äªº«~µP¤p²Õ¬[ºc¬ÛÃö³Ì¨Î¹ê°È¨å½d¡G«~µP±±¨î¤Î«~µP¤p²ÕºÞ²z
Best Practices in Designing Effective Brand Teams: Brand Governance and Brand Team Management
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 95058

¸gºÞ²z·ÓÅ@²z¥«³õ½Õ¬d¡]MMMR¡GManaged Markets Market Research)
Managed Markets Market Research: Effective Structures & Activities for Gaining Maximum Payer Access & Insight
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 95056

¦L«×«e10¤j»sÃÄ¥ø·~¡G¦¨ªøµ¦²¤・·~ÁZ・SWOT¤ÀªR
The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 94986

¬ü°êÃÄ«~¶}µo·~°È¨ü°U¾÷ºc¡]CRO¡^¥«³õ¡G¥D­nªvÀø»â°ì
U.S. CRO Markets - Key Therapeutic Areas
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 94650

°w¹ï«~µP¤W¥«¡B¦¨ªø¡B©µÄòªº¤½Ãö¬¡°Ê
Using Public Relations to Launch, Grow and Extend Your Brands
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 94429

«Ø¥ß»PFDAªº¦³®ÄÃö«Y
Building an Effective Regulatory Relationship with the FDA
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 94428

½T«O¥«³õÃö«Y¡G¸É¶K¡B»P¥I¶OªÌ¤§¶¡ªºÃö«Y¡BÂåÀø§ï­²
Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 94401

Lundbeck¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Lundbeck: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 19787

Pfizer¡G»sÃÄ¥ø·~¤ÀªR³ø§i
Pfizer: Pipeline, Products, Performance, Potential
¥Xª©¤é´Á : 2009/07
°Ó«~½s½X : 15643

ÃÄ«~¨ÑÀ³Ã쪺µ¦²¤
Filling the Holes in the Drug Supply Chain (Strategic Focus)
¥Xª©¤é´Á : 2009/06
°Ó«~½s½X : 94110

ÃĪ«・¶EÂ_²£«~¦@¦P¶}µoªº¥D­n°Ê¦V¡G¥ø·~¦X§@ªº¾÷·|¤Îªk³W½ÒÃD¤§¸Ñ¨M
Key Trends In Drug-diagnostic Co-development: Identifying collaborative opportunities and navigating regulatory challenges
¥Xª©¤é´Á : 2009/06
°Ó«~½s½X : 92690

·s¿³ÂåÀø¹êÅç¾ÚÂI¡]©Ô¤B¬ü¬w¡^¡G¥«³õ°Ê¦V¤ÎÅܰÊÂåÀø»â°ì¤Îªk³W­­¨îÀô¹Ò
Emerging Clinical Trial Locations -Latin America: Market dynamics and the changing healthcare and regulatory environment
¥Xª©¤é´Á : 2009/06
°Ó«~½s½X : 92689

·s¿³ÂåÀø¹êÅç¾ÚÂI¡]¦L«×¡^¡G¥«³õ°Ê¦V¤ÎÅܰʪºÂåÀø»â°ì¤Îªk³W­­¨îÀô¹Ò
Emerging Clinical Trial Locations - India: Market dynamics and the changing healthcare and regulatory environment
¥Xª©¤é´Á : 2009/06
°Ó«~½s½X : 92688


°ê»Ú»sÃÄ«´¬ù»P¦X§@¨ó©w
International Pharmaceutical Agreement (IPA)
Issues / Year : 12
°Ó«~½s½X : 4200

¤Ú¦è・«Xù´µ・¦L«×・¤¤°êÃÄ«~¥«³õ
The Market for Pharmaceuticals in Brazil, Russia, India & China 2009
Issues / Year : 4
°Ó«~½s½X : 99237